One place where we can learn more about psoriasis in people of color is in clinical trials. However, people with skin of color are drastically underrepresented in clinical trials for dermatology. The lack of diversity in clinical trials means that medications developed for conditions like psoriasis may not work as effectively for people with skin of color, and ultimately, the health equity gap continues to widen.

At UCB, people are at the heart of everything we do and part of our commitment to delivering impactful solutions for people whose lives have been challenged by severe disease is by deeply understanding their disease. This week is Hidradenitis Suppurativa (HS) Awareness Week and we’re sharing information on this lesser-known inflammatory, chronic autoimmune skin disease.

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21.